261 results about "Xanthine oxidase" patented technology

The invention discloses a xanthine oxidase inhibitory peptide with a kidney improving function and application thereof, and belongs to the technical field of biological medicines.The xanthine oxidase inhibitory peptide is screened out by conducting enzymolysis, separation and purification on litopenaeus vannamei processing by-products and utilizing a molecular docking technology, the amino acid sequence of the xanthine oxidase inhibitory peptide is Pro-Leu-Gly-Pro-Pro-Pro, and the amino acid sequence of the xanthine oxidase inhibitory peptide is Pro-Leu-Gly-Pro-Pro-Pro. And the half inhibition concentration of the polypeptide is 2.356 + / -0.2448 mM. The xanthine oxidase inhibitory peptide is proved to have an improvement effect on hyperuricemia mice, the improvement effect is mainly characterized by reducing the content of serum uric acid, creatinine and urea nitrogen of the hyperuricemia mice, inhibiting the activity of xanthine oxidase (XOD) in serum and livers of the mice, inhibiting synthesis of uric acid and improving kidney injury of the mice, and Toxinpred prediction shows that the xanthine oxidase inhibitory peptide has the effect of inhibiting the activity of xanthine oxidase (XOD) in the serum and livers of the mice. The xanthine oxidase inhibitory peptide is free of toxic and side effects, so that the xanthine oxidase inhibitory peptide has a wide application prospect in preparation of food or drugs for improving renal functions.

The invention discloses a xanthine oxidase inhibitory peptide with uric acid reducing activity and application thereof, and belongs to the technical field of biological medicines.The xanthine oxidase inhibitory peptide is obtained by conducting enzymolysis, separation and purification on processing byproducts such as litopenaeus vannamei heads and shells with xanthine oxidase inhibitory activity. The xanthine oxidase inhibitory peptide is screened by using a molecular docking technology, and the amino acid sequence of the xanthine oxidase inhibitory peptide is Pro-Pro-Val-Pro-Pro-Pro. The xanthine oxidase inhibitory peptide has an XOD (X-Oxidase) half inhibitory concentration of 3.181 + / -0.1786 mM. The invention further proves that the xanthine oxidase inhibitory peptide has a certain improvement effect on hyperuricemia mice, and the xanthine oxidase inhibitory peptide mainly has the effects of reducing the content of serum uric acid, creatinine and urea nitrogen of the hyperuricemia mice, inhibiting the activity of xanthine oxidase (XOD) in serum and liver of the mice, inhibiting synthesis of uric acid and improving kidney injury of the mice, and the xanthine oxidase inhibitory peptide has a certain improvement effect on the hyperuricemia mice through Toxinpred prediction. The xanthine oxidase inhibitory peptide uric acid reducing peptide is free of toxic and side effects and has a wide market application prospect.

The invention relates to the technical field of deep processing of phyllanthus emblica, in particular to phyllanthus emblica fermentation liquor and a preparation method thereof. The preparation method comprises the following steps: uniformly mixing crushed phyllanthus emblica pulp with water; after sterilization, adding lactic acid bacteria mixed powder for fermentation treatment; cellulase is added into the fermentation liquor for hydrolysis, and hydrolysate is obtained after enzyme deactivation; the hydrolysate is subjected to extraction treatment and solid-liquid separation, and the phyllanthus emblica fermentation liquor is obtained. By adopting the method disclosed by the invention, 107.11 mg of gallic acid, 360.76 mg of polyphenol and 65.56 mg of flavone can be extracted from each gram of the phyllanthus emblica raw material respectively, and the contents of gallic acid, polyphenol and flavone are increased by about 2.1 times, 4.5 times and 1.7 times respectively compared with those of gallic acid, polyphenol and flavone which are not subjected to fermentation treatment; the phyllanthus emblica fermentation liquor has alpha-glucosidase inhibitory activity, xanthine oxidase inhibitory activity, pancreatic lipase inhibitory activity, tyrosinase inhibitory activity and antioxidant activity; the phyllanthus emblica fermentation liquor is good in taste and flavor, and has the functions of reducing blood sugar, blood fat and uric acid and resisting oxidation.

The invention belongs to the technical field of medicines, and particularly relates to application of eupatorium chinense extract in preparation of a medicine for treating gout. Researches show that the eupatorium chinense extract and the active components thereof have good biological activity and can inhibit the activity of xanthine oxidase (XOD). Molecular docking experiments also show that the eupatorium chinense extract and xanthine oxidase have good binding energy. Further research finds that the eupatorium chinense extract can reduce the levels of uric acid and creatinine in serum in a hyperuricemia mouse body, and has good uric acid reducing activity. In the field of treatment of hyperuricemia and gout, many traditional medicines have many adverse reactions. Compared with the prior art, the eupatorium chinense serving as a traditional Chinese medicine provides a safe and effective natural medicine for treating hyperuricemia and gout or gout complications due to the efficient uric acid reducing effect of the eupatorium chinense.

The invention relates to the field of preparation and application of biological peptides, in particular to a swelling hippocampal peptide and application thereof in preparation of uric acid reducing and gout resisting products. The amino acid sequence is shown as SEQ ID NO.1. The uric acid reducing effect of the compound is proved through in-vitro xanthine oxidase (XOD) and adenosine deaminase (ADA) inhibition experiments and cell experiments; on the basis, the uric acid reducing and gout resisting activity of the peptide sequence is further verified by means of a hyperuricemia animal model. The achievement provides a solid theoretical support for high-value development and utilization of the hippocampus japonicus and research and development of uric acid reducing and gout resisting related products.

The invention provides lactobacillus fermentum as well as a compound preparation and application thereof, and relates to the technical field of microorganisms. Compared with a strain in the prior art, the lactobacillus fermentum HXJS4-1 disclosed by the invention has a better effect in the aspect of nucleoside degradation and can realize rapid nucleoside degradation. In addition, the compound has a stronger inhibition effect on xanthine oxidase, and the activity of the xanthine oxidase is effectively reduced. In mouse experiments, the strain also has an obvious uric acid reducing effect, also has a certain anti-inflammatory effect, can be used in the prevention and treatment process of hyperuricemia and gout, and provides a new probiotic or drug material for the treatment of hyperuricemia and gout. In addition, eating of the strain has no obvious influence on indexes of a sample body, and it is proved that the strain has the characteristic of high safety and can be widely applied to the fields of medicine and food.

The invention relates to an application of sea cucumber intestine polysaccharide in preparation of uric acid lowering drugs. The preparation method of the sea cucumber intestine polysaccharide comprises the following steps: performing enzymolysis treatment on sea cucumber intestines by using papain, performing enzyme deactivation, performing centrifugation, and taking supernate; and carrying out graded alcohol precipitation on the supernate, centrifuging, taking precipitate, deproteinizing and freeze-drying. The preparation method is simple, green and environment-friendly. The sea cucumber intestine polysaccharide prepared by the method can effectively inhibit the activity of xanthine oxidase; the sea cucumber intestine polysaccharide has no toxic effect on HK-2 cells. The compound has a uric acid reducing effect on HK-2 hyperuricemia cells.

The invention discloses camel milk polypeptide with xanthine oxidase inhibitory activity and application thereof.The camel milk polypeptide is prepared by taking fresh camel milk as a raw material, conducting low-temperature centrifugation to remove fat, conducting triple enzymolysis through papain, pepsin and trypsin to obtain enzymatic hydrolysate, enabling the enzymatic hydrolysate to pass through an ultrafiltration membrane (the molecular weight cutoff is 10 kDa) to obtain filtrate, and conducting freeze-drying to obtain the camel milk polypeptide. The compound has xanthine oxidase inhibitory activity. The invention also discloses a small molecule polypeptide with xanthine oxidase inhibitory activity. The filtered solution is screened and combined with polypeptides by adopting a xanthine oxidase affinity ultrafiltration method, the activity of the polypeptides is verified through molecular docking and in-vitro enzyme inhibition, four small-molecule polypeptides with xanthine oxidase inhibitory activity are obtained, the sequence of the small-molecule polypeptides is shown as any one of SEQ ID NO.1-4, and the small-molecule polypeptides can be used for preparing drugs with the effect of inhibiting the uric acid level.

A lactobacillus composition and the use thereof in hyperuricemia, relating to the field of microorganisms. The composition comprises Lactobacillus gasseri BDUP, Lactobacillus fermentum B1B26 and Lactobacillus agilis B13T4. The lactobacillus composition can significantly inhibit the activity of xanthine oxidase XOD in vitro, and, as proved by in-vivo experiments, said probiotic composition can also reduce the content of uric acid in Danio rerio having high uric acid levels and in hyperuricemia model mice and reduce the level of inflammatory factors in mice with hyperuricemia. In addition, the composition has effects obviously superior to that of a single strain and therefore has good development and utilization prospects for treating or preventing and relieving hyperuricemia.

The invention relates to the technical field of medicines, in particular to application of an active ingredient xanthohumol (XAN) derived from a traditional Chinese medicine humulus lupulus in preparation of medicines for reducing uric acid and resisting gout, and the xanthohumol (XAN) can be prepared into various oral preparations, injection preparations and external preparations with the assistance of pharmaceutically acceptable auxiliary materials and has good development and application prospects. The inventor finds that the xanthohumol has relatively strong effects of reducing blood uric acid, resisting inflammation, resisting bone damage and the like, and the mechanism of the effect of reducing the blood uric acid is that the activity of xanthine oxidase is inhibited so as to reduce the generation of uric acid, and the renal function of an organism is improved so as to enhance uric acid excretion; according to the anti-inflammatory effect, the inflammatory reaction is relieved mainly by down-regulating the levels of inflammatory factors such as IL-1beta, IL-6, TNF alpha and PEG2; the mechanism for resisting gout bone damage is realized through the fact that RANKL / OPG / RANK signal pathway participates in bone metabolism regulation.

The invention relates to euphausia superba peptide with uric acid reducing activity and application thereof. The euphausia superba peptide is a short peptide obtained by extraction, enzymolysis, separation and purification from degreased euphausia superba powder, and the amino acid sequence of the euphausia superba peptide is Ser-Ala-Gly-Lys-Thr. Researches show that the peptide can reduce the generation of uric acid by inhibiting the activity of xanthine oxidase and promote the excretion of uric acid. In-vitro cell experiments prove that under the concentration of 10 mu M, the inhibition rate of the peptide on xanthine oxidase reaches 23.1%; animal experiments show that the blood uric acid level of mice in a high-dose group (50mg / kg) is reduced by about 40% compared with that in a model group. The invention also develops a health-care beverage and a medicinal preparation which take the peptide as an active component, and provides a new choice for preventing and treating hyperuricemia and gout.

The invention relates to uric acid reducing probiotics obtained by high-throughput screening based on a silkworm model, in particular to a strain SWU-MY69, which is classified and named as Pediococcus pentosaceus, is preserved in China General Microbiological Culture Collection Center (CGMCC), has a preservation number of CGMCC No.31926, and is preserved in September 10, 2024. The pediococcus pentosaceus SWU-MY69 screened through a bombyx mori model has an excellent uric acid reducing effect, the inhibition rates of bacterial suspension, contents and metabolites of the strain on xanthine oxidase in vitro are all 80% or above, and the pediococcus pentosaceus SWU-MY69 also has an excellent inhibition effect on xanthine oxidase in vivo; uric acid in hemolymph is remarkably reduced, excretion of uric acid by intestinal tracts is promoted, and therefore the concentration of uric acid in serum is reduced, and burdens of kidneys and livers are reduced.

According to the preparation method disclosed by the invention, the whole fruit juice of the lonicera caerulea (which retains fruit residues) is fermented by virtue of the plant lactobacillus KLDS1.0391, KLDS1.0320 or KLDS1.0368, so that the xanthine oxidase (XO) inhibition activity is remarkably improved. After fermentation, the XO inhibition rate is increased to 48-50.87% (the content of unfermented juice is 31.21%), the total phenol content is increased by 15-24.3%, and the contents of main XO inhibitors in the lonicera caerulea: cyanidin-3-O-glucoside (IC50 = 115.28 [mu] M), cyanidin-3, 5-diglucoside (IC50 = 116.34 [mu] M), peonidin-3-glucoside (IC50 = 105.34 [mu] M), quercetin (IC50 = 88.75 [mu] M), catechin (IC50 = 110 [mu] M) and caffeoylquinic acid (IC50 = 250.35 [mu] M) are remarkably increased. Wherein the quercetin content is increased by 73.8% at most (KLDS1.0320 strain fermentation is performed for 24 hours), and the XO inhibition rate is increased from 31.21% to 50.87%. Technical support is provided for development of a natural XO inhibitor and a functional fermented beverage, so that a new thought is provided for functional fermented juice with lonicera caerulea as a key component.

The invention discloses an EGCG-Cu complex, an EGCG-Cu-Cs nanoparticle, a preparation method of the EGCG-Cu complex, and an application of the EGCG-Cu-Cs nanoparticle. The preparation method comprises the following steps: mixing an aqueous solution of EGCG and an aqueous solution containing copper ions, adjusting the pH value, stirring for reaction, dialyzing or centrifuging, and freeze-drying to obtain the EGCG-Cu complex; the EGCG-Cu complex is dissolved in water, a chitosan solution is added, stirring reaction, centrifugal washing and freeze drying are carried out, and the EGCG-Cu-Cs nanoparticles are obtained. The EGCG-Cu complex and the EGCG-Cu-Cs nanoparticles prepared by the invention are uniform in size and good in dispersity, and have excellent xanthine oxidase inhibition effect and free radical scavenging effect.

The invention discloses a siraitia grosvenorii instant coffee beverage assisting in reducing uric acid and a preparation method thereof, and belongs to the technical field of food based on the theory of homology of medicine and food. The coffee beverage is composed of instant coffee powder, a compound sweetening agent, coconut milk powder, milk powder and composite herbal powder in a specific proportion. The compound herbal powder is composed of poria cocos, peach kernels, dried tangerine or orange peel and momordica grosvenori which are selected from a medicinal and edible substance catalog. The herbal active ingredients and a coffee system are deeply fused by optimizing an extraction process, the dual regulation effects of inhibiting xanthine oxidase and promoting uric acid excretion are synergistically exerted, and the technical contradiction that common caffeine possibly affects uric acid excretion is effectively solved. The zebra fish in-vivo experiment proves that the level of uric acid can be remarkably reduced (Plt: 0.001), the improvement rate is as high as 17.63%, and a safe and effective daily diet intervention scheme is provided for people with hyperuricemia while the coffee flavor and convenience are provided.

The invention belongs to the technical field of microbial fermentation, and discloses lactobacillus mucilaginosus and application thereof in preparation of a uric acid reducing preparation. The survival rate of the fermented lactobacillus mucus in simulated gastric juice with the pH value of 2.0 for 3 hours is greater than 92%, the survival rate in simulated intestinal juice environment containing 0.5% of cholate is greater than 86%, and the viability of the fermented lactobacillus mucus is obviously higher than that of a conventional strain; and the tea has the effects of reducing uric acid, resisting oxidation and inhibiting pathogenic bacteria. The xanthine oxidase inhibition rate of the natural medicinal and edible compound potion obtained by mixing and co-fermenting the strain and existing bacterial powder is greater than 77% (45% or more higher than that of an unfermented group), and the oxidation resistance after fermentation can be improved by 50% at the same time. The beverage is suitable for being drunk as a daily functional food for a long time, and provides a natural and healthy collaborative diet relieving scheme for patients with hyperuricemia and gout.

The invention discloses a uric acid reducing composition and a preparation method and application of plant extracts of the uric acid reducing composition, and belongs to the technical field of traditional Chinese medicine formulas and preparation. The uric acid reducing composition is prepared from the following raw materials in parts by mass: 3 to 27 parts of corn stigma, 3 to 27 parts of pericarpium citri reticulatae and 3 to 27 parts of white kidney beans. The preparation method of the plant extract comprises the following steps: pretreating the raw materials, extracting effective components, compounding according to different proportions, evaluating the in-vitro xanthine oxidase inhibition effect by using the plant extract, determining the formula compatibility of the raw materials according to quantitative pharmacology, and further determining the formula compatibility of the uric acid reducing composition. The corn stigma is treated by adopting a steam wall breaking technology, so that the extraction rate of effective components of the corn stigma is remarkably improved, and the uric acid reducing effect of the product is enhanced; the uric acid reducing food prepared on the basis of the uric acid reducing composition is safe, free of side effects and suitable for being eaten by people with high uric acid for a long time.

The invention provides acid-resistant and cholate-resistant lactobacillus plantarum and application thereof, and relates to the technical field of microorganisms. The invention provides a strain with the capacity of degrading nucleic acid and inhibiting xanthine oxidase, namely lactobacillus plantarum HXJS3-1, and the lactobacillus plantarum HXJS3-1 has the effects of reducing the uric acid level and preventing and treating hyperuricemia and gout. In addition, the lactobacillus plantarum HXJS3-1 also has a certain anti-inflammatory effect and an effect of enhancing immunity. And a novel probiotic or medicine material is provided for treatment of hyperuricemia and related diseases thereof. The lactobacillus plantarum HXJS3-1 also has the characteristics of acid resistance, cholate resistance and no influence of existence of a carbon source and a nitrogen source, so that the lactobacillus plantarum HXJS3-1 can be widely applied to various scenes.

The invention discloses a bacterial medicine composition containing bacillus subtilis and application of the bacterial medicine composition in prevention and treatment of hyperuricemia, and belongs to the field of microorganisms, and the bacterial medicine composition containing bacillus subtilis BS01, radix clematidis and plumeria rubra can remarkably reduce the kidney index of mammals; the contents of blood uric acid, serum urea nitrogen and serum creatinine of mammals are obviously reduced; the activity of xanthine oxidase in the liver of the mammal is obviously reduced; the oxidation resistance of mammals, especially the GSH level of kidneys, is obviously improved; the expression quantity of ABCG2 mRNA of mammals is obviously increased; the uric acid level of an organism can be well reduced, and kidney function injury and kidney oxidative injury are relieved; the bacterial medicine composition can be used for preparing a medicine for preventing and treating hyperuricemia and a composition of the medicine, can also be used as an auxiliary product of an existing treatment medicine and an existing treatment method, can also be used as a microecological preparation to be applied to medicines or health-care products, and has very wide application prospects.

The invention provides peony polypeptide for reducing uric acid as well as a preparation method and application thereof, and belongs to the technical field of biology. The preparation method comprises the following steps: soaking and cleaning peony seed meal with ethanol, centrifuging at 3000-500r for 30-50min, taking a first precipitate, drying the first precipitate, adding water, adjusting the pH value to 9-10, carrying out alkali extraction at 45-55 DEG C for 70-80min, taking supernate, adjusting the pH value to an isoelectric point, and taking a second precipitate; the second precipitate is subjected to enzymolysis for 2-8 h under the conditions that the temperature is 20-80 DEG C, the pH is 5-9, and the protease addition amount is 1500-9000 U / g, and the peony polypeptide capable of reducing uric acid is obtained. The compound has inhibitory activity on xanthine oxidase, and the active components of the compound have stability and functionality by adopting ultrafiltration grading and simulated digestion model exploration.

The invention discloses an application of a conjugated ketene skeleton bromophenol compound in preparation of an anti-gout drug, the conjugated ketene skeleton bromophenol compound comprises BP-50 and BP-47, and experiments prove that the conjugated ketene skeleton bromophenol compound has remarkable inhibitory activity on xanthine oxidase, and can be used for preparing anti-gout drugs. The invention further studies the inhibition effect of the conjugated ketene skeleton bromophenol compound on MSU-induced inflammation taking NLRP3 inflammasome as a core, both BP-50 and BP-47 can inhibit secretion of MSU-induced characteristic inflammatory factors IL-1beta in a concentration-dependent manner, BP-50 down-regulates expression of NLRP3 inflammasome components by inhibiting an MAPK / NF-kappa B signal channel, and BP-47 can inhibit MSU-induced inflammation taking NLRP3 inflammasome components by inhibiting MAPK / NF-kappa B signal channel. The activation of the NLRP3 inflammasome is inhibited by reducing the ROS content, so that the activity of the NLRP3 inflammasome is reduced. It is proved that the conjugated ketene skeleton bromophenol compound can be used for preparing the anti-gout medicine, has a remarkable technical effect and has a wide market application prospect.

The invention relates to a preparation method and application of sea cucumber intestine polysaccharide. The preparation method of the sea cucumber intestine polysaccharide comprises the following steps: performing enzymolysis treatment on sea cucumber intestines by using papain, performing enzyme deactivation, performing centrifugation, and taking supernate; and carrying out graded alcohol precipitation on the supernate, centrifuging, taking precipitate, deproteinizing and freeze-drying. The preparation method is simple, green and environment-friendly. The sea cucumber intestine polysaccharide prepared by the method can effectively inhibit the activity of xanthine oxidase; the sea cucumber intestine polysaccharide has no toxic effect on HK-2 cells. The compound has a uric acid reducing effect on HK-2 hyperuricemia cells.

The invention discloses a uric acid reducing polypeptide, the polypeptide is derived from a peptide fragment, the'bindingerge 'value of the peptide fragment in molecular docking with xanthine oxidase is less than-1.5 kcal / mol, and the peptide fragment, in molecular docking with the xanthine oxidase, of the polypeptide is derived from a Peptide Ranker biological activity score gt; and 0.7 of a polypeptide. The uric acid reducing polypeptide is obtained by screening natto powder subjected to pepsin enzymolysis, natto powder enzymatic hydrolysate obtained through enzymolysis has the activity of inhibiting xanthine oxidase, the screened uric acid reducing polypeptide can be developed into a uric acid reducing medicine, and active ingredients are added into functional food and health food, so that the uric acid reducing polypeptide has a good application prospect. Good market prospects are realized in medicine and food industries.

The invention provides a uric acid reducing composition containing fructus gardeniae and a preparation method of the uric acid reducing composition, and belongs to the technical field of medicines. The preparation method comprises the following steps: fermenting mulberry leaves, chicory, cape jasmine and kudzu vine roots through lactobacillus rhamnosus and bifidobacterium longum, separating probiotics from fermentation liquor, adding immobilized ionic liquid into the fermentation liquor, introducing carbon dioxide for adsorption, filtering, adding solids into ethanol, heating for desorption, concentrating to obtain an extract 1, precipitating filtrate with ethanol to obtain an extract 2, and carrying out freeze-drying to obtain the folium mori-chicory-cape jasmine extract. The preparation method comprises the following steps: embedding probiotics together with sodium alginate to prepare a uric acid-reducing embedding material, and uniformly mixing the uric acid-reducing embedding material with the extract 1, vitamin C and tea polyphenol to prepare the uric acid-reducing composition containing fructus gardeniae. The prepared uric acid reducing composition containing fructus gardeniae can promote uric acid excretion, inhibit sodium urate crystallization, improve the antioxidant effect, repair intestinal barriers, relieve inflammation, inhibit xanthine oxidase (XOD) activity and expression and reduce the blood uric acid level, has a good uric acid reducing effect and has a wide application prospect.

The invention relates to the technical field of microorganisms, in particular to lactobacillus brevicornu MPA01 capable of adsorbing microplastics and degrading uric acid and application of the lactobacillus brevicornu MPA01. The preservation number of the lactobacillus brevis MPA01 is CGMCC (China General Microbiological Culture Collection Center) No. 31977. According to the present invention, the Lactobacillus brevicornu is the marine-derived natural strain, and has significant adsorption effects on the micro-plastics PS and PE, and the Lactobacillus brevicornu MPA01 and the plant lactobacillus MPs-68 are compounded so as to provide the synergistic effect on the adsorption effects on the micro-plastics PS and PE; besides, the strain has very high DPPH free radical scavenging rate and antioxidant capacity, is resistant to gastric acid and cholate, has better intestinal colonization capacity, also has certain inhibition capacity on xanthine oxidase, has remarkable capacity of degrading uric acid, and can be applied to the field of intestinal colonization. The method has important application value in the fields of food or health care products and the like for assisting adsorption of micro-plastics and reduction of uric acid.

Disclosed are an aqueous American ginseng extract, a method for preparing, and use thereof in reducing uric acid. The method comprises the following steps: grinding American ginseng, mixing with petroleum ether, and subjecting the mixture to ultrasonic extraction and filtration at reduced pressure; drying the defatted American ginseng powder and mixing with deionized water, and subjecting the mixture to another ultrasonic extraction and filtration at reduced pressure to give an aqueous American ginseng extract solution; and concentrating and lyophilizing the aqueous American ginseng extract solution to give the aqueous American ginseng extract. The resultant aqueous American ginseng extract can effectively reduce the activity of xanthine oxidase and adenosine deaminase, lower the blood uric acid level, and provide certain protective effects on the kidneys, thus possessing good development prospects.

The invention relates to the field of biological medicine, in particular to a decarboxylated carnosine composite liposome and application thereof in preparation of products for reducing uric acid and dissolving tophus. The decarboxylated carnosine composite liposome is formed by self-assembling raw materials including decarboxylated carnosine, alkaloid, flavone, a polygonum cuspidatum extract, p-coumaric acid, a liquorice extract, a semen coicis extract, a yam rhizome extract, a poria cocos extract and quercetin, and research proves that the decarboxylated carnosine composite liposome can reduce uric acid, dissolve ventilation stone and balance in-vivo acid-base balance; the composition inhibits xanthine oxidase from synthesizing uric acid, promotes uric acid excretion and intestinal tract movement in the body, repairs damaged liver and kidney cells, diminishes swelling, resists inflammation, relieves pain, prevents and treats hyperuricemia, relieves gout inflammation, reduces blood pressure and improves immunity.

The invention discloses a preparation method and application of hydrolyzed casein peptide capable of reducing uric acid and facilitating gout attack prevention and gout symptom improvement, belongs to the technical field of biology, and has a wide application prospect. The casein hydrolysate peptide prepared by the method disclosed by the invention can effectively reduce uric acid, and is beneficial to preventing gout attack and improving gout symptoms by the following ways: 1, inhibiting the activity of xanthine oxidase (UA enzyme), and reducing the generation of uric acid; 2, metal ions such as Ca < 2 + > and Na < + > are complexed to prevent generation of urate crystals, so that gout attack can be prevented; 3, the microenvironment of an articular cavity is improved, urate crystals are dissolved, and the gout symptom can be improved; and 4, liver and kidney inflammation caused by high uric acid is relieved.

The invention discloses application of polydatin in preparation of a medicine for relieving hepatotoxicity caused by zearalenone, and belongs to the technical field of biological medicine. The invention reveals that polydatin inhibits hepatotoxicity caused by zearalenone through targeted xanthine oxidase for the first time, so that the toxicity of zearalenone to an organism is relieved. Polydatin can be directly combined with xanthine oxidase to inhibit the catalytic activity of xanthine oxidase, so that the oxidative stress injury of the liver after ZEA exposure is reduced, meanwhile, the content of malondialdehyde (MDA) in the liver can be remarkably reduced, the activity of superoxide dismutase (SOD) is improved, the liver oxidation-antioxidant balance is recovered, and liver cells are protected from oxidative injury of ZEA. The invention provides a new scientific basis and development direction for application of polydatin in the fields of mycotoxin detoxification, oxidation resistance, liver protection and the like.

The invention relates to a food-borne melanin-containing uric acid-reducing food composition which is prepared by mixing 2-10 parts by weight of celery seed extract, 1-6 parts by weight of food-borne melanin and 0-5 parts by weight of astragalus extract, plays a role in reducing uric acid by inhibiting the activity of xanthine oxidase, and has a better effect of treating hyperuricemia and / or gout. The liver and kidney injury caused by hyperuricemia can be improved, the toxic and side effects are low, and the food can be eaten for a long time.